Alex Pasteur

Alex Pasteur began their career in 2012 as a Partner at F-Prime Capital Partners. In 2015, they became the Founding CEO of Orchard Therapeutics, a gene therapy company developing treatments for immuno-deficiencies and inherited metabolic diseases. Alex led the seed, Series A and Series B financings, licensed the core product pipeline, established the Scientific Advisory Board, and secured the first manufacturing partnership. Alex also hired the management team and built the first 50 employee base in London and Foster City, CA. In 2016, they became a Director at Oviva. In 2018, they became a Director at NodThera Limited and a Board Observer at Genomics plc. In 2019, they became a Director at Owkin. In 2020, they became a Director at Tenpoint Therapeutics and a Director at Arvelle Therapeutics, which was acquired by Angelini Pharma in January 2021. Alex also became a Board Observer at Pulmocide in 2013.

Alex Pasteur obtained a Master of Arts (MA) in Natural Sciences from the University of Cambridge in 1992 and a PhD in Chemistry from the same university in 1996.